Vertex Pharmaceuticals Incorporated
Leadership History
4 leaders · 1989 to present
Reshma Kewalramani is the CEO of Vertex Pharmaceuticals, in the role since 2020. The first chief executive was Joshua Boger, from 1989.
| Name | Role | From | To | Years in role |
|---|---|---|---|---|
| Reshma Kewalramani | Chief Executive Officer and President | 2020 | Present | 6 |
| Charles Wagner | EVP, Chief Operating and Financial Officer | 2019 | Present | 7 |
| Jeffrey Leiden | Chief Executive Officer | 2012 | 2020 | 8 |
| Joshua Boger | Founder and Chief Executive Officer | 1989 | 2009 | 20 |
Vertex is best understood as a focused biotech compounder. Its scientific base in cystic fibrosis created the cash flow, and that cash flow is now funding a broader specialty-medicine portfolio. The open question for the next decade is whether that one dominant franchise can pay for several new ones in pain, blood disorders, kidney disease, endocrinology, and type 1 diabetes before CF growth slows. The company is headquartered in Boston, Massachusetts.
Vertex earns almost all of its revenue from product sales of patented specialty medicines. Cystic fibrosis is the base: TRIKAFTA/KAFTRIO, the newer once-daily ALYFTREK, and older modulators such as KALYDECO, ORKAMBI, and SYMDEKO are sold to a relatively small, well-defined patient population at high per-patient prices that are negotiated with US payers and national health systems. Newer revenue comes from CASGEVY, the CRISPR-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia that Vertex co-owns with CRISPR Therapeutics and delivers through authorized treatment centers, from JOURNAVX (suzetrigine), a non-opioid pill for moderate-to-severe acute pain, and, since September 2026, from PALSONIFY for acromegaly, acquired with Crinetics. Cash flow from cystic fibrosis funds a large R&D budget and acquisitions such as Alpine Immune Sciences (2024) and Crinetics (2026).
Chief Executive Officer and President
2020 – Present
6 years (current)
Oversaw the approvals of CASGEVY (2023), JOURNAVX (2025), and ALYFTREK (2024), and led the acquisitions of Alpine Immune Sciences (2024) and Crinetics Pharmaceuticals (2026).
A nephrologist who joined Vertex from Amgen in 2017 and served as Chief Medical Officer before becoming CEO in April 2020; her tenure has focused on diversifying Vertex beyond cystic fibrosis.
EVP, Chief Operating and Financial Officer
2019 – Present
7 years (current)
Wagner managed the massive cash flow generated by Trikafta to fund the complex $3.2 billion acquisition of Alpine Immune Sciences, heavily diversifying Vertex into immunology.
As CFO, he ensures the company maintains the massive R&D budget required to develop the highly anticipated non-opioid painkiller (VX-548).
Chief Executive Officer
2012 – 2020
8 years
Leiden engineered the aggressive commercialization of Kalydeco and the subsequent triple-combination therapy Trikafta, effectively turning Cystic Fibrosis from a fatal disease into a manageable condition.
As CEO from 2012 to 2020, he transformed Vertex from a struggling biotech with a failed Hepatitis C drug into a massive, highly profitable monopoly in CF treatments.
Founder and Chief Executive Officer
1989 – 2009
20 years
Boger left Merck in 1989 to found Vertex, built around structure-based drug design.
He led the research that produced the hepatitis C drug telaprevir and the first cystic fibrosis medicines. Matthew Emmens succeeded him in 2009.
Vertex's biggest challenge is concentration. Cystic fibrosis remains the revenue engine, which means reimbursement pressure, patent duration, competitive innovation, or slower uptake of next-generation CF products could affect the whole company. The newer businesses also carry execution risk: CASGEVY requires complex treatment-center workflows, JOURNAVX must earn adoption against cheap pain medicines, and kidney or diabetes programs still depend on clinical and regulatory success. Biotechnology investors reward the company for scientific focus, but that focus also makes failed trials more visible.
Vertex has been led by founding CEO Dr. Joshua Boger (1989–2009), Matthew Emmens (2009–2012), Dr. Jeffrey Leiden (2012–2020), and Dr. Reshma Kewalramani (April 2020–present).
Dr. Boger established the rational drug design platform, recruited elite biophysicists, navigated the volatile early clinical pipeline, and forged the critical partnership with the Cystic Fibrosis Foundation that yielded Kalydeco.
Dr. Leiden, a cardiologist and former Abbott executive, commercialized Kalydeco, Orkambi, Symdeko, and Trikafta, grew revenues from under $200 million to over $6 billion, moved headquarters to Fan Pier, and initiated the CRISPR gene therapy partnership.
Dr. Reshma Kewalramani earned her medical degree with honors from Boston University, trained in internal medicine and nephrology at Harvard's Massachusetts General Hospital, and spent over a decade in R&D at Amgen before joining Vertex in 2017.
She served as Vertex's Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs, overseeing the rapid clinical development and global approvals of Symdeko and Trikafta.
She became the first female Chief Executive Officer of a large US biotechnology company (market cap >$20B) and one of the few practicing physician-scientists leading a top global biopharma firm.
Under her leadership, Vertex secured FDA approval for CASGEVY (first-ever CRISPR therapy), completed Phase 3 development of suzetrigine for acute pain, advanced vanzacaftor to global filing, and acquired Alpine Immune Sciences for $4.9B.
Dr. Kewalramani has been named to Fortune's Most Powerful Women, Forbes' 50 Over 50, and Boston Magazine's Most Influential Bostonians, and serves on the board of directors of the Biomedical Science Careers Program.
She champions a physician-scientist culture of uncompromising biological rigor, encouraging researchers to follow causal human genetics and "fail early" on projects that do not show transformative efficacy.
Key leaders include Dr. David Altshuler (Chief Scientific Officer and Broad Institute co-founder), Charles Wagner (Chief Financial Officer), and Stuart Arbuckle (Chief Operating Officer).
Executive compensation is heavily aligned with clinical pipeline advancement, regulatory approvals, total shareholder return (TSR) relative to the NASDAQ Biotechnology Index, and product revenue targets.
To transform Vertex from a single-disease cystic fibrosis company into a multi-franchise, serial innovator curing and treating life-threatening diseases across genetic medicine, pain, and cell therapy.
Compare executive leadership tenures and strategic transitions
Explore Vertex Pharmaceuticals
Core profile pages, founders and related research hubs for this company.